Crossmark

Treatment and monitoring of Philadelphia chromosome-positive leukemia patients: recent advances and remaining challenges

Crossref DOI link: https://doi.org/10.1186/s13045-019-0729-2

Published Online: 2019-04-23

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Soverini, Simona http://orcid.org/0000-0002-4508-0353
Bassan, Renato

Lion, Thomas
License Information

Text and Data Mining valid from 2019-04-23
More Information

Article History

Received: 16 February 2019

Accepted: 2 April 2019

First Online: 23 April 2019

Ethics approval and consent to participate

: Not applicable

: Not applicable

: SS has been a consultant for Incyte Biosciences, Novartis, and Bristol-Myers Squibb. TL has been a consultant for and received honoraria from Incyte, Angelini, Ariad, Pfizer, Novartis, Amgen, and Bristol-Myers Squibb as well as research support from Novartis and Incyte. RB has been a consultant for and received honoraria from Incyte, Ariad, Pfizer, Amgen, and Shire.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.